AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (40 µg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 µg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg) + Ipratropium (40 µg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (6 mg) + Salbutamol (200 µg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 (1.5 or 6 mg)
Number of subjects: 66
Study 30166326 — intervention group
Group type: EXPERIMENTAL
Intervention: RPL554 combined with standard bronchodilators
Number of subjects: 66
Study 30166326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27612991 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram dosing adjusted for gender and postmenstrual age (GrA)
Number of subjects: 85
Study 27612991 — intervention group
Group type: COMPARATOR
Intervention: Doxapram dosing based on infants' weight alone (GrW)
Number of subjects: 85
Study 22121008 — intervention group
Group type: COMPARATOR
Intervention: Apical ballooning syndrome (ABS) group
Number of subjects: 12
Study 22121008 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-elevation myocardial infarction (STEMI) group
Number of subjects: 12
Study 22248750 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (HES130/0.4)
Number of subjects: 42
Study 22248750 — intervention group
Group type: COMPARATOR
Intervention: Lactate Ringer solution (RL)
Number of subjects: 42
Study 20701510 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/day)
Number of subjects: 285
Study 20701510 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 285
Study 17432077 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 139
Study 17432077 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 139
Study 16336059 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received education and a reminder card describing risk factors of CVD.
Number of subjects: 160
Study 16336059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 160
Study 11887131 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 microgram/kg/min
Number of subjects: 40
Study 11887131 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 50 mg
Number of subjects: 40
Study 11887131 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study 11887131 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 40
Study 10462387 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus interferon (9 microg) given three times weekly for 24 weeks
Number of subjects: 420
Study 10462387 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (3 million units) given three times weekly for 24 weeks
Number of subjects: 420
Study 7603929 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopedagogical intervention programme
Number of subjects: 0
Study 2195704 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g Almarin capsules (fish oil concentrate) daily for 12 weeks
Number of subjects: 111
Study 2195704 — intervention group
Group type: COMPARATOR
Intervention: Olive oil control
Number of subjects: 111
Study 29912406 — intervention group
Group type: EXPERIMENTAL
Intervention: glo™ (mentholated or non-mentholated variants)
Number of subjects: 180
Study 29912406 — intervention group
Group type: EXPERIMENTAL
Intervention: iQOS (non-mentholated variant)
Number of subjects: 180
Study 29912406 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit nicotine and tobacco product use completely
Number of subjects: 180
Study 29912406 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarettes (control group)
Number of subjects: 180
Study 28501763 — intervention group
Group type: EXPERIMENTAL
Intervention: six cycles of FEC 100 (Arm A)
Number of subjects: 1515
Study 28501763 — intervention group
Group type: COMPARATOR
Intervention: four cycles of FEC 100 (Arm B)
Number of subjects: 1515
Study 26887213 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-elongated needle group
Number of subjects: 100
Study 26887213 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture group
Number of subjects: 100
Study 23359185 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC + DC/CIK (120 mg/m(2) docetaxel, 175 mg/m(2) thiotepa, with or without 400 mg/m(2) carboplatin)
Number of subjects: 166
Study 23359185 — intervention group
Group type: COMPARATOR
Intervention: Standard dose chemotherapy (SDC) (75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa)
Number of subjects: 166
Study 22097348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanjin tablet
Number of subjects: 68
Study 22097348 — intervention group
Group type: COMPARATOR
Intervention: Conventional sensitive antibiotics
Number of subjects: 68
Study 19698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/d
Number of subjects: 615
Study 19698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 615
Study 19698901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 19698901 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 615
Study 16685007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg/d
Number of subjects: 141
Study 16685007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 1280 microg/d
Number of subjects: 141
Study 16685007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 16685007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide treatment groups
Number of subjects: 141
Study 16685007 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 141
Study 15542162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous cream
Number of subjects: 357
Study 15542162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate cream
Number of subjects: 357
Study 15542162 — intervention group
Group type: COMPARATOR
Intervention: No cream (control)
Number of subjects: 357
Study 11380297 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG three times (group I)
Number of subjects: 413
Study 11380297 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG on the day of embryo transfer + daily vaginal progesterone (group II)
Number of subjects: 413
Study 11380297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone only (group III)
Number of subjects: 413
Study 11380297 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG in combination with daily vaginal progesterone (group IV)
Number of subjects: 413
Study 11380297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone only (group V)
Number of subjects: 413
Study 11380297 — intervention group
Group type: COMPARATOR
Intervention: hCG only or additional injection of hCG
Number of subjects: 413
Study 9233866 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (3.6 mg subcutaneously every four weeks for three years)
Number of subjects: 415
Study 9233866 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 415
Study 7654898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20-40 mg) with hypolipemiant dietetic treatment
Number of subjects: 16
Study 7654898 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietetic treatment only)
Number of subjects: 16
Study 3300232 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium)
Number of subjects: 17
Study 3300232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30115007 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with BIS monitoring and warming
Number of subjects: 70
Study 30115007 — intervention group
Group type: COMPARATOR
Intervention: Non-desflurane anesthesia (control group)
Number of subjects: 70
Study 26945818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.257% w/v
Number of subjects: 51
Study 26945818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 40 ml
Number of subjects: 51
Study 25181766 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reinforcement (TR)
Number of subjects: 0
Study 25181766 — intervention group
Group type: COMPARATOR
Intervention: Negotiated maintenance contract without TR
Number of subjects: 0
Study 22294813 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test
Number of subjects: 34
Study 22294813 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls matched for age, sex, and BMI)
Number of subjects: 34
Study 21087499 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol added to standard treatment
Number of subjects: 44
Study 21087499 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 44
Study 19125710 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed saphenous venous bypass
Number of subjects: 121
Study 19125710 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene/dacron bypass
Number of subjects: 121
Study 15908318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys
Number of subjects: 197
Study 15908318 — intervention group
Group type: COMPARATOR
Intervention: Roferon-A
Number of subjects: 197
Study 14501856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Number of subjects: 58
Study 14501856 — intervention group
Group type: COMPARATOR
Intervention: Postoperative Thymoglobulin (1 mg/kg/dose, 3 to 6 doses during the first week posttransplant)
Number of subjects: 58
Study 14501856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Thymoglobulin
Number of subjects: 58
Study 10434160 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (200 to 300 mg/day)
Number of subjects: 123
Study 10434160 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (30 to 40 mg/day)
Number of subjects: 123
Study 8794438 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 (0.5 mg every other day) + Ca (0.5 g/day)
Number of subjects: 214
Study 8794438 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 + Ca + sCT (50 IU x 2/day)
Number of subjects: 214
Study 8794438 — intervention group
Group type: EXPERIMENTAL
Intervention: sCT + Ca
Number of subjects: 214
Study 8794438 — intervention group
Group type: COMPARATOR
Intervention: Ca
Number of subjects: 214
Study 1806878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 40
Study 1806878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6352626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g iv dose
Number of subjects: 29
Study 31157663 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4612
Study 31157663 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4612
Study 30486799 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Mental Health Practice Support Program (AMHPSP) training for family physicians
Number of subjects: 129
Study 30486799 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 129
Study 26037521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 μg/d)
Number of subjects: 105
Study 26037521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 24675102 — intervention group
Group type: COMPARATOR
Intervention: Parenteral corticosteroid (PS) (n=33)
Number of subjects: 86
Study 24675102 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nebulized steroid (NB) (n=27)
Number of subjects: 86
Study 24675102 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nebulized steroid (NB) (n=26)
Number of subjects: 86
Study 22090186 — intervention group
Group type: EXPERIMENTAL
Intervention: High maternal expressed emotion (EE)
Number of subjects: 0
Study 22090186 — intervention group
Group type: EXPERIMENTAL
Intervention: High child expressed emotion (EE) regarding fathers
Number of subjects: 0
Study 22090186 — intervention group
Group type: EXPERIMENTAL
Intervention: High child and maternal expressed emotion (EE)
Number of subjects: 0
Study 22090186 — intervention group
Group type: EXPERIMENTAL
Intervention: High child expressed emotion (EE) regarding parents
Number of subjects: 0
Study 20932869 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant
Number of subjects: 3000
Study 20932869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 17919549 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate 10.8 mg plus iron (ferrous sulfate 325 mg TID)
Number of subjects: 110
Study 17919549 — intervention group
Group type: COMPARATOR
Intervention: Sham (iron monotherapy)
Number of subjects: 110
Study 15902631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography (Mx)
Number of subjects: 613
Study 15902631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 613
Study 15902631 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 613
Study 12074599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg/day for six weeks)
Number of subjects: 40
Study 12074599 — intervention group
Group type: COMPARATOR
Intervention: Control group (LOC subjects before supplementation)
Number of subjects: 40
Study 12074599 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIC subjects)
Number of subjects: 40
Study 10335420 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg for weeks 1 and 2, 30 mg for weeks 3 and 4, twice daily)
Number of subjects: 14
Study 10335420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10335420 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 7497554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (Group PS, n = 21)
Number of subjects: 40
Study 7497554 — intervention group
Group type: COMPARATOR
Intervention: Ankle block (Group AB, n = 19)
Number of subjects: 40
Study 7497554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral popliteal sciatic nerve block (Group PS)
Number of subjects: 40
Study 7497554 — intervention group
Group type: COMPARATOR
Intervention: Ankle block (Group AB)
Number of subjects: 40
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from Pittman Moore (PM) or Pasteur Virus (PV) strains
Number of subjects: 35
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from European Bat Lyssavirus (EBL)
Number of subjects: 35
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated and purified rabies viruses (IPRV) from Mokola (Mok) rabies-related virus strains
Number of subjects: 35
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from PV viruses
Number of subjects: 35
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from EBL viruses
Number of subjects: 35
Study 1771968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribonucleoprotein (RNP) from Mok viruses
Number of subjects: 35
Study 6749996 — intervention group
Group type: EXPERIMENTAL
Intervention: Propidium iodide (PI)
Number of subjects: 0
Study 6749996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamidinophenylindol (DAPI)
Number of subjects: 0
Study 6749996 — intervention group
Group type: COMPARATOR
Intervention: Ethidium bromide (EB)
Number of subjects: 0
Study 6749996 — intervention group
Group type: EXPERIMENTAL
Intervention: EB-FITC combination
Number of subjects: 0
Study 6749996 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-FITC combination
Number of subjects: 0
Study 6749996 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPI-TRITC combination
Number of subjects: 0
Study 28139973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 191
Study 28139973 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected-limb-position
Number of subjects: 191
Study 28139973 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 191
Study 28139973 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 191
Study 28139973 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet
Number of subjects: 191
Study 29986268 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline adherence measured by salivary varenicline levels
Number of subjects: 376
Study 29986268 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal metabolizers (NMR≥0.31)
Number of subjects: 376
Study 29986268 — intervention group
Group type: COMPARATOR
Intervention: Pill counts (self-reported adherence)
Number of subjects: 376
Study 28427456 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with atrial natriuretic peptide (ANP) administration for 3 days during the perioperative period
Number of subjects: 500
Study 28427456 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 500
Study 25300791 — intervention group
Group type: EXPERIMENTAL
Intervention: EP‐RDP
Number of subjects: 54
Study 25300791 — intervention group
Group type: COMPARATOR
Intervention: C‐RDP
Number of subjects: 54
Study 24125415 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (140 mL providing approximately 500 mg dietary nitrate)
Number of subjects: 20
Study 24125415 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 20
Study 24125415 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 20
Study 21912118 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin (CG1)
Number of subjects: 0
Study 21912118 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and carboplatin (CG8)
Number of subjects: 0
Study 18981948 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 23
Study 18981948 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 23
Study 17012004 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 elastic compression hosiery
Number of subjects: 300
Study 17012004 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 3 elastic compression hosiery
Number of subjects: 300
Study 14613435 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs) as maintenance treatment for persistent asthma
Number of subjects: 0
Study 14613435 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a long-acting inhaled beta2-agonist or a leukotriene modifier to ICS therapy
Number of subjects: 0
Study 14613435 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective measures of pulmonary function
Number of subjects: 0
Study 14613435 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity assessment
Number of subjects: 0
Study 11106715 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 microg subcutaneously once per week for 48 weeks)
Number of subjects: 531
Study 11106715 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2a (6 million units subcutaneously three times per week for 12 weeks, followed by 3 million units three times per week for 36 weeks)
Number of subjects: 531
Study 11106715 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 531
Study 11106715 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2a
Number of subjects: 531
Study 9296405 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine 70 microg/kg
Number of subjects: 226
Study 9296405 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 150 microg/kg
Number of subjects: 226
Study 27719743 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 after low-fat meal
Number of subjects: 36
Study 27719743 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 after high-fat meal
Number of subjects: 36
Study 27719743 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg LCZ696 under fasting condition
Number of subjects: 36
Study 3943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible vessels
Number of subjects: 129
Study 3943691 — intervention group
Group type: COMPARATOR
Intervention: Other stigmata of recent hemorrhage
Number of subjects: 129
Study 3943691 — intervention group
Group type: COMPARATOR
Intervention: No stigmata of recent hemorrhage
Number of subjects: 129
Study 3943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent partial gastrectomy
Number of subjects: 129
Study 3943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological changes in bleeding artery
Number of subjects: 129
Study 3943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer penetration
Number of subjects: 129
Study 3943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean external diameter of bleeding artery
Number of subjects: 129
Study 29847828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity for 12 weeks
Number of subjects: 23
Study 29847828 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 27041256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted transversus abdominis plane (TAP) block
Number of subjects: 80
Study 27041256 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration (INF)
Number of subjects: 80
Study 24978674 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (im testosterone undecanoate) for 40 weeks
Number of subjects: 88
Study 24978674 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 88
Study 23484301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber post and composite resin core
Number of subjects: 135
Study 23484301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure titanium casting post and core
Number of subjects: 135
Study 23484301 — intervention group
Group type: COMPARATOR
Intervention: No treatment (direct restoration)
Number of subjects: 135